| 产品描述: | SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM. |
| 参考文献: |
1. Yingqiang Liu, et al. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma. Acta Pharm Sin B. 2023, 13,12. |
| 保存条件: |
-80°C 6个月; -20°C 1个月,避光 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.436 ml |
12.182 ml |
24.364 ml |
| 5 mM |
0.487 ml |
2.436 ml |
4.873 ml |
| 10 mM |
0.244 ml |
1.218 ml |
2.436 ml |
| 50 mM |
0.049 ml |
0.244 ml |
0.487 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |